GA²LEN, the Global Allergy and Asthma European Network, brings
together multidisciplinary research teams that address allergic
diseases in their globality. Understanding common risk factors
and mechanisms will contribute to improve treatment and quality
of life for up to 150-200 million Europeans with allergies and
asthma.

The GA²LEN research platform will endure after the period of EU financing.
From 2009 on, the network will be self-sustainable and welcome research and
education activities in allergy and asthma of European or international scale

Sixth Framework Programme

The Sixth Framework Programme ran from 2004 until 2010. Research teams were chosen for their scientific excellence, their record on multidisciplinary working and international collaboration, and their educational activities. Since the launch of the Network, it has grown to include an additional 50 collaborating centres making GA²LEN one of the largest multidisciplinary networks of researchers in allergy and asthma worldwide.

A platform for researchers

GA²LEN provides an integrated platform for research in allergy
and asthma with harmonised tools and methods in its centres.
The network that has now centres in 20 countries can benefit
from the European diversity for risk factors studies and prevention
schemes. Pilot protocols for clinical studies in several GA²LEN
centres have been tested, which could open the door to further
public-private collaboration. The network aims at developing
novel biomarkers, treatment and preventive strategies.

Guidelines and life long learning

GA²LEN promotes the development of a high-level, large scale
international and multidisciplinary scientific community. Allergy
schools, training sessions and e-learning support the clinical and
research activities of junior scientists and health professionals.
Scientists can use the GA²LEN communication platform and
programmes for mobility and exchange.

For patients, public and policy makers

The prevalence of allergic diseases has been increasing in the European population over the last decades, most clearly in children. Allergic diseases are currently insufficiently diagnosed, suboptimally managed and, generally undertreated. GA²LEN contributes to raising awareness on this public health problem and develops educational material for patients and the general public.